Pinned Tweet
🩺💡The Bitterman lab has spend much of the past year researching #LLMs for healthcare. This post summarizes our inroads into making LLMs safer and reliable for clinicians and patients: huggingface.co/blog/shanchen….
We'll be at #EMNLP2024 - come chat if you have similar interests!
Danielle Bitterman, MD retweeted
Great work! Understanding trials are certainly v important and underrated!
Thanks for using medbrowsecomp!
Announcing Parallel for Healthcare: upgrades to our index and ranking that put Parallel on the cost-accuracy frontier for healthcare AI search.
- Parallel delivers top accuracy across four healthcare benchmarks: PWS-Health, LitQA3, TrialQA, and MedBrowseComp
- On PWS-Health, our new healthcare-focused benchmark, Parallel delivers 1.4x more correct answers per dollar than the next-best engine
- On LitQA3, Parallel is the most accurate engine, with 1.7x more correct answers per dollar than the next-best engine
Healthcare answers sit deep in FDA labels, ClinicalTrials.gov records, and the methods sections of papers, rarely in the abstract.
@AcuityMD verified 574K records at 1/5 the cost of a frontier model using Parallel.
Danielle Bitterman, MD retweeted
Read about an AI agent assisting clinicians in assessing immune-related adverse events now in Nature Cancer!
@dbittermanmd
nature.com/articles/s43018-0…
Thank you for highlighting our study @EricTopol !
Agentic AI detected adverse events of cancer immunotherapy, which are frequently missed, in real world medicine
nature.com/articles/s43018-0…
Danielle Bitterman, MD retweeted
🤖 #ESMOAI26 Watch Prof. Jakob Kather while he shares his vision and invites you to attend the second edition of the ESMO AI & Digital Oncology Congress 2026. Register by 28 October and save.
🔗 ow.ly/x3Gp50ZKhF0
#esmomeetings
Danielle Bitterman, MD retweeted
I got to know @rachnatshroff through our time together on the @ASCO Nominating Committee. She is a dynamo. How she manages to balance a successful career as a clinical trialist with her huge administrative roles alongside her volunteerism to groups like ASCO & @SWOG will never cease to amaze me -- all the while showing an unrelenting commitment to friends & family.
I'll never forget the kindess Dr. Shroff extended to my junior faculty at @cityofhope - @gagan_brar24 & @DaniCastilloMD - after I requested she meet with them to provide external mentorship. The @ConquerCancerFd Endowed Young Investigator Award is on theme with the leadership & altriusm she has shown throughout her career. Let's all band together to support this:
support.conquer.org/p2p/site…
Danielle Bitterman, MD retweeted
🤖 #ESMOAI26 : From autonomous AI systems to real-world deployment in oncology, your work can help shape the conversation. Submit your abstract by 1 September.
🔗 ow.ly/4b0u50ZgPmu
#esmomeetings
Danielle Bitterman, MD retweeted
Our team wrapped up the ASCO LDP program yesterday by presenting our group project on "Strengthening Trust in Oncology" to the @ASCO Board.
Thank you to our coaches, classmates & whole ASCO team for a great year plus lifelong friendships 🎉!
Danielle Bitterman, MD retweeted
Amazing start of #ASCO26 at the @carisls POA Summit, @mystlukes was very well represented. Got also the chance to listen to Jorge Reis-Filho, congratulate @dbittermanmd for her new AI role at @AstraZeneca, and hanging out with Sajjad Bhatti, @EladSharonMD and many others.
Danielle Bitterman, MD retweeted
Wonderful to hear from @AstraZeneca’s new VP for AI in Clinical Development, @dbittermanmd on her thoughts on the future of #AI in precision oncology!
Danielle Bitterman, MD retweeted
Nowhere will be better than SF+COLM
Shoutout to plp that make this happen!: @YuexingHao @YuxinXiao6, @hzhang0, @StellaLisy, @adoubleva, @tom_hartvigsen, @jasonafries, @ang3linawang, @tsvetshop, @MarzyehGhassemi
@dbittermanmd @Majeans2011 @sanmikoyejo @martin_sen @2plus2make5
Very excited to be joining AZ to tackle the critical question in AI for drug development: How can AI speed up, improve success rate, and improve availability of clinical trials without compromising our high safety and evidentiary standards?
AstraZeneca recruited physician scientist @dbittermanmd from her research lab within the AI in Medicine Program at Mass General Brigham & Dept of Radiation Oncology at the Brigham 2b VP of AI for Clinical Development. She'll be leading clinical AI across R&D at $AZN. Congrats!
Danielle Bitterman, MD retweeted
🤖 AI is changing oncology faster than ever and your research could shape the next era of cancer care. Submit your abstract to #ESMOAI26 by 1 September 2026
🔗 ow.ly/ashE50YYyiq
#esmomeetings
AI in Cancer Research and Care: What We’ve Learned and What Comes Next? Charlotte Bunne, Danielle Bitterman, & Alexander Pearson explored this question in an #AACR26 session moderated by Benjamin Haibe-Kains & Christina Curtis. @bhaibeka @_bunnech @dbittermanmd @lab_pearson
Danielle Bitterman, MD retweeted
Thank you to the presenters and attendees at our inaugural #AI in #Cancer Workshop—highlighting how AI is advancing early detection and enabling more personalized cancer care. A day filled with valuable insights & new collaborations. @SmilowCancer @WilliamOhMD @MeinaWang @maryam_lustberg @dbittermanmd @SanjayAnejaMD @Fridsma @YaleRadiology @MonicaValero16
Danielle Bitterman, MD retweeted
🌟Introducing the advisory board for ASCO AI in Oncology:
🔹Editor-in-Chief Ravi B. Parikh, MD, MPP, FACP @ravi_b_parikh
🔹Kenneth L. Kehl, MD, MPH
🔹Danielle S. Bitterman, MD @dbittermanmd
🔹Travis Zack, MD, PhD
🔹Jame Abraham, MD, FACP @jamecancerdoc
ascoai.org/editorial-advisor…
Danielle Bitterman, MD retweeted
#FollowFriday Elad Sharon is a medical oncologist at the Dana-Farber Cancer Institute, where he is the Clinical and Translational Director of the Immunotherapy Toxicity Program and a Member of the Faculty of Medicine at Harvard Medical School.
Dr. Sharon is seeking to develop innovative clinical trials to better understand the side effects associated with immune checkpoint inhibitors and other immunotherapy agents. Follow him! @DanaFarber @EladSharonMD
Danielle Bitterman, MD retweeted
We believe this is a step toward rigorous, future-facing evaluation for AI Scientists.
Explore the code, data, and offline sandbox here:
- Paper: arxiv.org/abs/2601.07606
- Code: github.com/shan23chen/proof_…
Led by Bingyang Ye and @shan23chen and supported by Jingxuan Tu, @ChenLiu_1996, @polaris_7369, and @dbittermanmd
Danielle Bitterman, MD retweeted
🔬📚 Can LLM agents predict the future of science?
We introduce Proof of Time to evaluate scientific idea judgment at scale (30k+ instances).
Danielle Bitterman, MD retweeted
Peer review is slow. Citations lag.
But what if ground truth is just… time?
⏳ Proof of Time (PoT): forecast post-cutoff impact (cites/awards/SOTA/faculty moves) from frozen evidence.
📷Paper + data out now → arxiv.org/abs/2601.07606
Let time be the judge.
Danielle Bitterman, MD retweeted
Proof of Time ⏳
let the future itself grade AI's scientific judgment.
Freeze evidence at t₀ →
predict citations, awards, SOTA shifts, faculty trajectories at t₁ → score when truth arrives.
Offline sandbox + agent scaling inside
huggingface.co/blog/shanchen…


































